Craig A Hokanson

Title: The Innovative Contributions of Craig A. Hokanson

Introduction

Craig A. Hokanson is a notable inventor based in Pleasanton, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors. With a total of 5 patents to his name, Hokanson's work has the potential to impact therapeutic approaches in cancer treatment.

Latest Patents

Hokanson's latest patents include innovative technologies such as "Fibronectin binding domain chimeric antigen receptors and methods of use thereof." This patent describes chimeric antigen receptors (CARs) designed for binding with target antigens, featuring at least one antigen-specific targeting region that comprises a fibronectin type 3 (FN3) domain polypeptide. Additionally, he has developed multispecific chimeric antigen receptors that can bind with two or more target antigens, enhancing the versatility of CAR therapies. Another significant patent is for "Universal fibronectin type III binding-domain libraries," which details FN3 polypeptide libraries used to identify binding peptides with high affinities for VEGFR2 or Axl proteins.

Career Highlights

Throughout his career, Craig A. Hokanson has worked with various companies, including Protelica, Inc. and Protelix, Inc. His experience in these organizations has contributed to his expertise in the field of biotechnology and innovation.

Collaborations

Hokanson has collaborated with notable individuals in the industry, including Roberto Crea and Guido Cappuccilli. These partnerships have likely enriched his research and development efforts.

Conclusion

Craig A. Hokanson's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic applications.